About tyra biosciences inc - TYRA
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
TYRA At a Glance
Tyra Biosciences, Inc.
2656 State Street
Carlsbad, California 92008
| Phone | 1-619-728-4760 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -119,947,000.00 | |
| Sector | Health Technology | Employees | 87 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TYRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.448 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.959 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.004 |
TYRA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,378,701.149 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TYRA Liquidity
| Current Ratio | 14.671 |
| Quick Ratio | 14.671 |
| Cash Ratio | 14.149 |
TYRA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -36.955 |
| Return on Equity | -39.828 |
| Return on Total Capital | -45.265 |
| Return on Invested Capital | -39.104 |
TYRA Capital Structure
| Total Debt to Total Equity | 2.242 |
| Total Debt to Total Capital | 2.193 |
| Total Debt to Total Assets | 2.045 |
| Long-Term Debt to Equity | 2.06 |
| Long-Term Debt to Total Capital | 2.014 |